Here, we were able to contribute to the understanding of how ERK3 promotes TNBC progression and possible metastasis formation, warranting future studies to determine whether ERK3 could serve as a valuable therapeutic target or biomarker in TNBC and other subtypes of breast cancer, such as HER2+. Here, ERBB2 is linked to breast carcinoma.